[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rhinosinusitis-chronic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rhinosinusitis-chronic":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100554647","biologics-in-severe-nasal-polyposis-survey-a-french-registry-100554647",false,"NCT06501807","BIOlogics in Severe Nasal POlyposis SurvEy.: a French Registry","Real Life Assessment of Biologics Efficacy in Severe Chronic Rhinosinusitis With Nasal Polyps","BIOPOSE2","Inclusion Criteria:\n\n* Patients of over 18-year old requiring a biologic treatment for CRswNP in accordance with its marketing approval.\n* The patients already treated according to this criteria since August 2021 will be followed and their previous clinical and biological data retrospectively collected\n\nExclusion Criteria:\n\n* Oral corticotherapy in the previous month;\n* Biologic treatment with anti-IgE (omalizumab), anti-IL-5\u002FIL-5R (mepolizumab, benralizumab) or anti-IL-4\u002FIL-13R (dupilumab) or any other biotherapy for inflammatory diseases in the previous 6 months of initiation of treatment apart from ongoing biotherapies for severe asthma or CRSwNP;\n* Hypersensitivity to humanized antibodies ;\n* Documented SARS-Cov2 infection in the last 3 months with persistent olfactory disorders related to COVID;\n* Pregnant or breast-feeding women;\n* Patient without social coverage.","ALL","18 Years",{"count":20,"type":21},900,"ESTIMATED","INTERVENTIONAL",[24],"NA","With a prevalence of 2-4% in western countries, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is of major concern regarding its substantial impact on the social and physical quality of life. So far, endoscopic sinus surgery remains the treatment of choice when the first line of medical treatment with corticosteroid has failed.\n\nDuring the last 15 years, several studies have shown that CRSwNP is associated with a T helper 2 (T2) immune response leading to B cell release of IgE, mucosal recruitment of eosinophils from bone marrow via Interleukin (IL)-5, IL-4 and IL-13 mediated chemoattractant production.\n\nNew biologic agents capable of blocking T2 cytokines have been developed in the field of eosinophil-associated diseases, shifting the paradigm of treatment for patients with CRSwNP. In the near future, endotype profiling with accurate biomarkers will be mandatory to tailor the treatment of nasal polyposis with specific biologic therapies.\n\nHerein the investigators propose a prospective study monitoring medical records of CRSwNP patients who undergo biologic treatments. The objectives are to assess treatment efficacy on quality of life, to report clinical and biological criteria for prescription and to measure tolerance and compliance.Patient-reported outcomes will be addressed according to their initial clinical profile (allergy, asthma, NSAID, gastroesophageal reflux disease, obstructive apnea, otologic disorder, smoke habit).",[27,28],"Rhinosinusitis Chronic","Nasal Polyps",[30,31,32,33],"nasal polyp","chronic rhinosinusitis","eosinophil","endotype","RECRUITING","2026-05-14",{"date":37,"type":38},"2026-05-18","ACTUAL",{"date":40,"type":38},"2024-07-11",{"date":42,"type":21},"2035-01-02",{"name":44,"class":45},"University Hospital, Lille","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100565433","evaluation-of-the-safety-and-performance-of-a-bioresorbable-nasal-dressing-containing-mometasone-furoate-100565433","NCT06642116","Evaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate","ENHANCE","Inclusion Criteria:\n\n1. Patient is 18 years or older\n2. Patient is scheduled to undergo bilateral endoscopic sinus surgery for Chronic Rhinosinusitis with nasal polyps (CRSwNP) or Chronic Rhinosinusitis without nasal polyps (CRSsNP)\n3. Patient is willing and able to comply with all study elements as indicated by their written informed consent\n4. Patients with a pre-operative Lund-MacKay score of ≥ 6.\n\nExclusion Criteria:\n\n1. Patient is pregnant or nursing\n2. Patients with a history of chronic epistaxis or experienced a significant epistaxis event (defined as epistaxis requiring medical intervention) in the past 3 months\n3. Patients with a platelet disorder\n4. Patients with a known or suspected allergy to device components\n5. Patients with known hemophilia\n6. Patients with insulin dependent diabetics\n7. Patients with an oral steroid dependent condition\n8. Patients with glaucoma, ocular hypertension, posterior subcapsular cataracts\n9. Patients with a (previous) diagnosis of Samter's Triad (aspirin-exacerbated respiratory disease (AERD))\n10. Patients that require nasal ointments or creams at time of device placement\n11. Patients with a neurological, medical, psychiatric condition, or social circumstance that would potentially increase risk, interfere with study participation, or confound interpretation of study data\n12. Patients with plans to (or otherwise anticipate the need to) undergo an ear, nose, throat (ENT) procedure within the 90 day study follow up\n13. Patients participating in another clinical research study (within 30 days prior to screening up till 90 days post-operative).\n14. Patients that used any form of corticosteroid or immunologics within 2 weeks prior to sinus surgery or during follow-up to day 30.",{"count":54,"type":21},20,[24],"The objective of this study is to investigate the safety and performance of OCEAN® as an adjunct in wound healing after nasal\u002Fsinus surgery by using OCEAN® in patients undergoing nasal\u002Fsinus surgery.",[27,58,59,60],"Wound Healing","Sinus Surgery","Mometasone Furoate","NOT_YET_RECRUITING","2024-10-11",{"date":64,"type":38},"2024-10-15",{"date":66,"type":21},"2024-11",{"date":68,"type":21},"2025-07",{"name":70,"class":71},"Polyganics BV","INDUSTRY"]